{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:03:46Z","timestamp":1783699426405,"version":"3.55.0"},"reference-count":15,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>A 26-year-old man undergoing therapy with 45\u2009mg ustekinumab (Stelara) for chronic psoriasis vulgaris was referred by his general practitioner to an infectious diseases department for fatigue, fever, night sweating, generalised lymphadenomegaly and unexplained weight loss. Physical examination revealed bilateral occipital, cervical, axillary and inguinal lymphadenomegalies in addition to splenomegaly. Preliminary investigation revealed elevated Plasmodium lactate dehydrogenase and an inversion of the CD4\/CD8 ratio. Whole-body spiral CT scanning with and without contrast showed splenomegaly and highlighted supradiaphragmatic and subdiaphragmatic lymphadenopathies. A complete Infectious Disease Test Panel revealed high levels of anti-<jats:italic>Toxoplasma gondii<\/jats:italic> antibodies. Immunoglobulin G avidity was negative. Peripheral blood lymphocyte phenotyping was performed to exclude underlying lymphatic neoplasia. The diagnosis of severe acute toxoplasmosis infection in the setting of immune response modifiers was made. Ustekinumab was suspended indefinitely and the patient underwent monthly serological tests to monitor the immune response until all symptoms resolved and the serological testing was negative for Toxoplasma.<\/jats:p>","DOI":"10.1136\/bcr-2019-230415","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T03:45:20Z","timestamp":1565927120000},"page":"e230415","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Severe acute toxoplasmosis infection following ustekinumab treatment in a patient with psoriasis vulgaris"],"prefix":"10.1136","volume":"12","author":[{"given":"Muhammad A","family":"Muslimani","sequence":"first","affiliation":[{"name":"Facolta di Medicina, Universita degli Studi di Pavia Facolta di Medicina e Chirurgia, Pavia, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-5572","authenticated-orcid":false,"given":"James","family":"Di Palma-Grisi","sequence":"additional","affiliation":[{"name":"Facolta di Medicina, Universita degli Studi di Pavia Facolta di Medicina e Chirurgia, Pavia, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"2025082802463340000_12.8.e230415.1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895"},{"key":"2025082802463340000_12.8.e230415.2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2025082802463340000_12.8.e230415.3","doi-asserted-by":"publisher","DOI":"10.1038\/nri3707"},{"key":"2025082802463340000_12.8.e230415.4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025082802463340000_12.8.e230415.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.20.2337"},{"key":"2025082802463340000_12.8.e230415.6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025082802463340000_12.8.e230415.7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jdcr.2017.09.020","article-title":"Plurifocal cutaneous leishmaniasis during treatment with ustekinumab","volume":"4","author":"Rakotonarivo","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2025082802463340000_12.8.e230415.8","doi-asserted-by":"crossref","first-page":"ofy259","DOI":"10.1093\/ofid\/ofy259","article-title":"Acute toxoplasma dissemination with encephalitis in the era of biological therapies","volume":"5","author":"Gharamti","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2025082802463340000_12.8.e230415.9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/107327489700400510","article-title":"Toxoplasmic lymphadenopathy clinically presenting as lymphoma","volume":"4","author":"Quiroz","year":"1997","journal-title":"Cancer Control"},{"key":"2025082802463340000_12.8.e230415.10","first-page":"570","article-title":"Clinical approach to lymphadenopathy","volume":"20","author":"Pangalis","year":"1993","journal-title":"Semin Oncol"},{"key":"2025082802463340000_12.8.e230415.11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/cei.13261","article-title":"Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab","volume":"196","author":"Mojtahed Poor","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"2025082802463340000_12.8.e230415.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141550","article-title":"Intracellular Networks of the PI3K\/AKT and MAPK Pathways for Regulating Toxoplasma gondii-Induced IL-23 and IL-12 Production in Human THP-1 Cells","volume":"10","author":"Quan","year":"2015","journal-title":"PLoS One"},{"key":"2025082802463340000_12.8.e230415.13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.5997"},{"key":"2025082802463340000_12.8.e230415.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500690"},{"key":"2025082802463340000_12.8.e230415.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-012-0339-3"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-230415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:46:41Z","timestamp":1756374401000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-230415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,15]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bcr-2019-230415"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-230415","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}